Please login to the form below

Mayzent

This page shows the latest Mayzent news and features for those working in and with pharma, biotech and healthcare.

Novartis’ MS therapy Mayzent approved by NICE

Mayzent then received approval from the European Commission (EC) earlier this year, again for the treatment of adults with active SPMS. ... According to NICE, around 11, 000 people with SPMS will now be eligible to receive Mayzent treatment.

Latest news

Novartis wins FDA approval for relapsing MS drug Kesimpta

Kesimpta’s approval in relapsing MS builds on Novartis’ existing presence in the therapy area, which includes its active secondary progressive multiple sclerosis (SPMS) therapy Mayzent (siponimod).
Novartis builds its case for novel MS treatment ofatumumab

The drug is an important product in Novartis’ growing MS franchise, which currently includes Mayzent (siponimod), a next-generation treatment approved for use in active secondary progressive multiple sclerosis (SPMS).
J&J aims for US approval of MS drug ponesimod

If approved, ponesimod will compete directly with Novartis’ S1P receptor modulator franchise, which includes Gilenya (fingolimod) and follow-up Mayzent (siponimod), which is approved for secondary progressive forms of MS only
Biogen triumphs over Mylan’s Tecfidera patent challenge

language. Although the patent dispute is an overwhelming win, Biogen has been facing other challenges in the MS market from new treatments, including Novartis’ newly-approved Mayzent and Roche’s Ocrevus.
Cosentyx, Entresto drive topline growth for Novartis in Q4

Novartis also highlighted success in its approvals from 2019: this included Zolgensma, breast cancer treatment Piqray (alpelisib), multiple sclerosis drug Mayzent (siponimod), wet age-related macular degeneration treatment Beovu (brolucizumab) and

More from news
Approximately 5 fully matching, plus 20 partially matching documents found.

Latest Intelligence

Drug launches to watch in 2019

4. Mayzent – a latest addition to competitive MS market. Novartis’ Mayzent (siponimod) is expected to be launched in the US in Q1 for multiple sclerosis, with an EU launch to follow

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Account Manager Healthcare / Pharmaceutical Sector: Negotiable Salary

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

Healthcare Lead Copywriter: Competitive

Medical Editor: Competitive

Healthcare Account Director: Competitive

Account Director – Creative Healthcare Communications: Competative

Healthcare Senior Account Manager: Competitive

PMHub

Add my company

Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

The search for effective drug treatments for COVID-19: PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...
AstraZeneca’s focus on diagnosing and managing chronic kidney disease: People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
Delphi Technique Virtual Co-creation: A Customer Story: How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....